Vascodagama Online Journal

Tenosynovial Giant Cell Tumors (TSGCTs) Clinical and Commercial Assessment of the Pipeline Therapies, Market Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Tenosynovial Giant Cell Tumors (TSGCTs) Clinical and Commercial Assessment of the Pipeline Therapies, Market Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

July 16
18:34 2021
Delveinsight Business Research LLP

DelveInsight’s “Tenosynovial Giant Cell Tumors (TSGCTs) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors (TSGCTs) Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Tenosynovial giant cell tumors (TGCT), also known as Pigmented Villonodular Synovitis (PVNS), is a rare disease that arises from the synovium, bursae, and tendon sheaths of young adults between 20 and 40 years of age. Origination and history of trauma remain controversial. TGCT is classified as a localized type or diffuse type according to the extent of synovial involvement and the location. The diffuse type (D-TGCT) usually affects larger

These tumors are often classified by their growth pattern (localized or diffused) and location (intra- or extra-articular. When the tumor involves the tendons that support the joint or occurs in just one area of the joint, it is called localized PVNS. It is a rare, benign proliferating disorder of the synovium that can be locally aggressive affecting the joints, tendon sheaths, and bursa. Diffuse PVNS presented clinically as chronic mono-arthritis, commonly with hemarthrosis.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market

The Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Tenosynovial Giant Cell Tumors (TSGCTs) market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Tenosynovial Giant Cell Tumors (TSGCTs) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Tenosynovial Giant Cell Tumors (TSGCTs) Market

Tenosynovial Giant Cell Tumors (TSGCTs) Market Key Facts

  • As per the Rasuli et al., in the third to fifth decades female is likely to be predilected with an M: F ratio of 1.5–2.1:1. They are the second most common soft tissue mass of the hand and wrist.

  • According to Lmerini et al., in Italy, the annual incidence for TGCT is estimated at 10 (lt-TGCT) and 4 (dt-TGCT) cases per million people, with a slight female dominance and most new diagnoses between 40 and 59 years of age.

  • The total diagnosed incident population of Tenosynovial Giant Cell Tumors (TSGCTs) in the seven major markets was found to be 13,580 cases in 2017.

  • Among the EU5 countries, Germany had the maximum diagnosed incident population of TSGCTs i.e., 953 cases followed by the United Kingdom with 726 cases in 2017. While the lowest number of cases were found in Spain with 551 cases in 2017.

  • Japan accounted for 2,346 cases of diagnosed Tenosynovial Giant Cell Tumors (TSGCTs) in 2017, which is expected to increase in the forecast period 2021–2030.

Key Benefits of Tenosynovial Giant Cell Tumors (TSGCTs) Market Report

  • The market report provides an in-depth analysis of Tenosynovial Giant Cell Tumors (TSGCTs) Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Tenosynovial Giant Cell Tumors (TSGCTs) Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Tenosynovial Giant Cell Tumors (TSGCTs) current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Tenosynovial Giant Cell Tumors (TSGCTs) market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Tenosynovial Giant Cell Tumors (TSGCTs) Market 

The market size of Tenosynovial Giant Cell Tumors (TSGCTs) is expected to grow during the forecast period owing to the launch of upcoming therapies in the 7MM. Increasing awareness and changing lifestyles will also drive market growth.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Tenosynovial Giant Cell Tumors (TSGCTs) Market Size and Share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Tenosynovial Giant Cell Tumors (TSGCTs) Market Trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology

The epidemiology section covers insights about the historical and current Tenosynovial Giant Cell Tumors (TSGCTs) patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Tenosynovial Giant Cell Tumors (TSGCTs) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tenosynovial Giant Cell Tumors (TSGCTs) Market or expected to get launched in the market during the study period. The analysis covers Tenosynovial Giant Cell Tumors (TSGCTs) market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Tenosynovial Giant Cell Tumors (TSGCTs) Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Tenosynovial Giant Cell Tumors (TSGCTs) pipeline possesses potential drugs in late and mid-stage developments to be launched in the near future.

Tenosynovial Giant Cell Tumors (TSGCTs) Companies:

  • Novartis 

  • AmMax Bio

  • Daiichi Sankyo

  • Five Prime Therapeutics

  • Deciphera Pharmaceuticals

And many others.

Tenosynovial Giant Cell Tumors (TSGCTs) Therapies covered in the report include:

  • Tasigna (also known as Nilotinib, AMN107)

  • Lacnotuzumab (MCS-110)

  • Cabiralizumab 

  • AMB-05X

  • Vimseltinib (DCC-3014) 

And many more.

 Table of Content

1. Key Insights

2. Executive Summary 

3. Tenosynovial Giant Cell Tumors (TSGCTs) Competitive Intelligence Analysis

4. Tenosynovial Giant Cell Tumors (TSGCTs) Market Overview at a Glance

5. Tenosynovial Giant Cell Tumors (TSGCTs) Disease Background and Overview

6. Tenosynovial Giant Cell Tumors (TSGCTs) Patient Journey

7. Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology and Patient Population

8. Tenosynovial Giant Cell Tumors (TSGCTs) Treatment Algorithm, Current Treatment, and Medical Practices

9. Tenosynovial Giant Cell Tumors (TSGCTs) Unmet Needs

10. Key Endpoints of Tenosynovial Giant Cell Tumors (TSGCTs) Treatment

11. Tenosynovial Giant Cell Tumors (TSGCTs) Marketed Products

12. Tenosynovial Giant Cell Tumors (TSGCTs) Emerging Therapies

13. Tenosynovial Giant Cell Tumors (TSGCTs) Seven Major Market Analysis

14. Attribute Analysis

15. Tenosynovial Giant Cell Tumors (TSGCTs) Market Outlook (7 major markets)

16. Tenosynovial Giant Cell Tumors (TSGCTs) Access and Reimbursement Overview

17. KOL Views on the Tenosynovial Giant Cell Tumors (TSGCTs) Market.

18. Tenosynovial Giant Cell Tumors (TSGCTs) Market Drivers

19. Tenosynovial Giant Cell Tumors (TSGCTs) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market

Latest Reports By DelveInsight

Tenosynovial Giant Cell Tumors (TSGCTs) Pipeline Insights

Tenosynovial Giant Cell Tumors (TSGCTs) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Tenosynovial Giant Cell Tumors (TSGCTs) market.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/